[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rheumatoid-arthritis-ra-prevention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rheumatoid-arthritis-ra-prevention":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100650912","development-and-evaluation-of-the-effectiveness-of-the-smart-hand-protocol-for-hand-rehabilitation-in-patients-with-rheumatoid-arthritis-100650912",false,"NCT07754552","Development and Evaluation of the Effectiveness of the SMART-HAND Protocol for Hand Rehabilitation in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* Participants will be 18 years of age or older.\n* Participants will have a diagnosis of rheumatoid arthritis for at least five years.\n* Participants will be referred by a rheumatologist.\n* Participants will have been on a stable medication regimen for the past three months.\n* Participants will have no history of diabetes mellitus.\n* Participants will have no other conditions affecting sensory function.\n* Participants will provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Individuals who have undergone hand surgery within the past six months.\n* Individuals with a history of upper extremity fracture within the past six months.\n* Individuals with other musculoskeletal pain conditions involving the muscles and\u002For joints.\n* Individuals diagnosed with a neurological disease that may affect sensory or motor function.\n* Individuals who are unable to fully cooperate with the assessment procedures.\n* Individuals who have received corticosteroid treatment within the past month.\n* Individuals diagnosed with another rheumatic disease.\n* Pregnant women.\n* Individuals who are illiterate.\n\nWithdrawal\u002FDiscontinuation Criteria\n\n* Participants who miss more than 10% of the intervention sessions will be excluded from the study.\n* Participants who change their medication dosage or medication class during the study period will be excluded from the study.\n* Participants will have the right to withdraw from the study at any time and for any reason.","ALL","18 Years",{"count":18,"type":19},132,"ESTIMATED","INTERVENTIONAL",[22],"NA","Rheumatoid arthritis (RA) frequently affects the hand and wrist, resulting in pain, reduced joint stability, impaired proprioception, muscle weakness, and limitations in daily activities. Although conventional rehabilitation primarily focuses on range of motion and strengthening exercises, sensorimotor impairments such as proprioceptive deficits are often underaddressed. The SMART-HAND (Sensory, Massage, Approximation, ROM, Training = Strengthening + Perturbation) protocol was developed as a structured, mechanism-based rehabilitation program to improve proprioception, joint stability, motor control, and hand function. This randomized controlled trial aims to evaluate the effectiveness of the SMART-HAND protocol in individuals with RA by comparing its effects on hand function, proprioception, pain, dexterity, muscle strength, and functional performance with conventional rehabilitation and a control group.",[25,26,27],"Rheumatoid Arthritis","Rheumatoid Arthritis (RA","Rheumatoid Arthritis (RA) Prevention",[25,29,30,31,32,33,34],"Hand Rehabilitation","Hand Function","Proprioception","Neuromuscular Control","Grip Strength","Joint Stability","NOT_YET_RECRUITING","2026-08-13",{"date":38,"type":39},"2026-08-14","ACTUAL",{"date":41,"type":19},"2026-10-01",{"date":43,"type":19},"2027-12-30",{"name":45,"class":46},"Istanbul University - Cerrahpasa","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100599814","efficacy-and-safety-of-resveratrol-in-patients-with-rheumatoid-arthritis-100599814","NCT07089381","Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Adult patients \\> 18 years old\n* Established diagnosis of RA according to American College of Rheumatology\u002FEuropean league Against Rheumatism (ACR\u002FEULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n* Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.\n* RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n\nExclusion Criteria:\n\n* Patients receiving biologic DMARDs therapy for RA\n* Patients taking any other anti-inflammatory drugs\n* Patients taking any other antioxidants\n* Pregnant and lactating women\n* Other rheumatological, inflammatory diseases or malignancies\n* Smokers\n* Thyroid illnesses\n* Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin)",{"count":54,"type":19},118,[22],"The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis.\n\nObjectives :\n\n1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring:\n\n   * Serum Sirtuin 1(SIRT1)\n   * Serum Myeloperoxidase (MPO)\n   * Serum C-reactive protein (CRP)\n2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score).\n3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI).\n4. To assess any adverse effects related to Resveratrol.\n\nPatients:\n\nEligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups:\n\n1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months.\n2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.",[58,27,59,60,61,62,63,64,65],"Rheumatic Arthritis","Inflamation","Antioxidant","Anti Oxidative Stress","Anti Aging","C Reactive Protein","Methotrexate","Quality of Life Outcomes","RECRUITING","2025-07-21",{"date":69,"type":39},"2025-07-28",{"date":71,"type":19},"2025-08-01",{"date":73,"type":19},"2026-06-01",{"name":75,"class":46},"Ain Shams University",1]